Clinical Trials
16 trialsNCT06950385 2026-06-02
SERENTA
Rapamycin Holdings Inc.
Phase 3 Recruiting
NCT05919264 2026-05-28
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT05552755 2026-04-16
TUPELO
Recursion Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT03649971 2025-02-03
A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
Janssen Research & Development, LLC
Phase 1 Completed
NCT04948398 2025-02-03
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
Janssen Research & Development, LLC
No longer available
NCT04230499 2025-01-09
Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
Rapamycin Holdings Inc.
Phase 2 Active not recruiting
NCT00151476 2024-09-04
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
Pfizer
Terminated
NCT03806426 2024-04-25
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
S.L.A. Pharma AG
Phase 3 Unknown
NCT05014360 2023-06-02
A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
Janssen Research & Development, LLC
Phase 1 Completed
NCT01483144 2021-06-08
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Completed
NCT00585312 2021-02-21
CHIP
Pfizer
Phase 3 Terminated
NCT00140894 2019-09-20
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 4 Terminated
NCT00663819 2018-04-17
Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses
W.L.Gore & Associates
Phase NA Terminated
NCT01245816 2015-04-24
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Withdrawn
NCT01002287 2014-11-20
An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery
Integra LifeSciences Corporation
Phase NA Terminated
NCT00510692 2014-08-22
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
S.L.A. Pharma AG
Phase 2/3 Completed